Company intelligence / Profile preview
北京同御康泰科技
Beijing, Beijing, Chinatykt-tech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Beijing Tongyu Kangtai Technology is a clinical-stage biotechnology company based in Beijing, China, focused on the development of innovative small molecule targeted therapies for cancer. The company's primary focus is on addressing resistance mechanisms in oncology, particularly through the development of next-generation kinase inhibitors. Its lead asset, TY-2136, is a potent ROS1/NTRK/ALK inhibitor currently undergoing clinical evaluation for the treatment of non-small cell lung cancer and other advanced solid tumors. Tongyu Kangtai aims to provide precision medicine solutions for patients who have failed existing targeted therapies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on 北京同御康泰科技.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 北京同御康泰科技.